Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Oct 25, 2022

BUY
$1.04 - $322.5 $4,260 - $1.32 Million
4,097 New
4,097 $7,000
Q1 2022

Apr 14, 2022

SELL
$0.62 - $1.17 $868 - $1,638
-1,400 Closed
0 $0
Q4 2021

Jan 18, 2022

BUY
$1.09 - $1.89 $109 - $189
100 Added 7.69%
1,400 $1,000
Q3 2021

Oct 26, 2021

BUY
$1.44 - $2.73 $432 - $819
300 Added 30.0%
1,300 $2,000
Q2 2021

Jul 19, 2021

BUY
$2.63 - $3.67 $2,630 - $3,670
1,000 New
1,000 $2,000
Q1 2019

May 10, 2019

SELL
$2.0 - $4.4 $2,094 - $4,606
-1,047 Closed
0 $0
Q4 2018

Feb 05, 2019

SELL
$1.61 - $3.62 $16,175 - $36,370
-10,047 Reduced 90.56%
1,047 $1,000
Q3 2018

Nov 07, 2018

BUY
$2.26 - $3.27 $12,536 - $18,138
5,547 Added 100.0%
11,094 $33,000
Q2 2018

Aug 10, 2018

SELL
$3.02 - $4.94 $1,812 - $2,964
-600 Reduced 9.76%
5,547 $16,000
Q1 2018

May 11, 2018

BUY
$3.46 - $5.14 $5,190 - $7,709
1,500 Added 32.28%
6,147 $24,000
Q4 2017

Jan 17, 2018

SELL
$4.0 - $6.54 $7,200 - $11,772
-1,800 Reduced 27.92%
4,647 $19,000
Q3 2017

Oct 17, 2017

BUY
$4.99 - $6.57 $32,170 - $42,356
6,447
6,447 $39,000

Others Institutions Holding TCRT

About Alaunos Therapeutics, Inc.


  • Ticker TCRT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 216,182,000
  • Market Cap $443M
  • Description
  • Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...
More about TCRT
Track This Portfolio

Track Cutler Group LP Portfolio

Follow Cutler Group LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.